The International Serious Adverse Event Consortium (iSAEC) is a nonprofit organization founded in 2007. It is comprised of leading pharmaceutical companies, the Wellcome Trust, and academic institutions; with scientific and strategic input from the U.S. Food and Drug Administration (FDA) and other international regulatory bodies. The mission of the iSAEC is to identify DNA-variants useful in predicting the risk of drug-related serious adverse events (SAEs)
The goal of the National Institute for Health Research (NIHR) is to create a health research system in which the NHS supports outstanding individuals, working in world class facilities, conducting leading edge research focused on the needs of patients and the public. The NHS reputation for international excellence is growing as it gains recognition for being the preferred host for collaborative and multi-centred research in the public interest in partnership with and for industry. This will benefit patients, society, the NHS and all our stakeholders.
The International IBD Genetics Consortium is a network of researchers working on the genetics of inflammatory bowel disease. We have undertaken a number of large scale genome-wide association studies of both Crohn’s disease and ulcerative colitis, which have identified dozens of genomic loci implicated in these diseases.
Crohn’s and Colitis UK aims to improve life for everyone affected by Inflammatory Bowel Disease (IBD), the most common forms being Crohn’s Disease and Ulcerative Colitis. Together these conditions affect about 250,000 people in the United Kingdom.
The British Society of Gastroenterology (BSG) exists to maintain and promote high standards of patient care in gastroenterology and to enhance the capacity of its members to discover and apply new knowledge to benefit patients with digestive disorders. Our members include physicians, surgeons, pathologists, radiologists, scientists, nurses. dietitians, and others.
The Renal Association is the professional body for United Kingdom nephrologists (renal physicians, or kidney doctors) and renal scientists in the UK. It is active in the planning and development of renal services and nephrology in Britain. It is also involved in the promotion and dissemination of research and education relating to the specialty.
ECCO strive for optimising the care for patients with IBD in all aspects. As part of this mission ECCO will adopt and further all efforts that lead to an improvement of the use of current therapies and procedures. Main aims include the developments of guidelines with highest possible process and content quality and joint efforts to define better and more valid outcome parameters for the therapy of IBD.